Cargando…

Bacillus spp. Spores—A Promising Treatment Option for Patients with Irritable Bowel Syndrome

Dysbiosis is a condition that can cause various clinical disorders, from gastrointestinal problems to allergies or even cancer. Resetting the microbiota using antibiotics and/or probiotics could be a possible therapy for many diseases. The aim of this study was to evaluate the effects of three treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Catinean, Adrian, Neag, Adriana Maria, Nita, Andreea, Buzea, Mihaela, Buzoianu, Anca Dana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770835/
https://www.ncbi.nlm.nih.gov/pubmed/31438618
http://dx.doi.org/10.3390/nu11091968
_version_ 1783455575424630784
author Catinean, Adrian
Neag, Adriana Maria
Nita, Andreea
Buzea, Mihaela
Buzoianu, Anca Dana
author_facet Catinean, Adrian
Neag, Adriana Maria
Nita, Andreea
Buzea, Mihaela
Buzoianu, Anca Dana
author_sort Catinean, Adrian
collection PubMed
description Dysbiosis is a condition that can cause various clinical disorders, from gastrointestinal problems to allergies or even cancer. Resetting the microbiota using antibiotics and/or probiotics could be a possible therapy for many diseases. The aim of this study was to evaluate the effects of three treatment regimens in patients with irritable bowel syndrome (IBS). The regimens were short-term rifaximin treatment (10 days) followed by either a nutraceutical agent (G1) or a low- Fermentable, Oligo-, Di-, Monosaccharide and Polyol (FODMAP) diet (24 days) (G3) or treatment with MegaSporeBiotic a mixture of spores of five Bacillus spp. for medium-term (34 days) (G2). Ninety patients with IBS without constipation were enrolled and divided into three groups (G1, G2, G3). Patients in G1 and G3 were evaluated over four visits (baseline/first day (V1), 10 days (V2), 34 days (V3), 60 days (V4)), and, those in G2 over three visits (V1, V3, V4). Severity score, quality of life, and parameters from the rectal volume sensation test were determined. The results demonstrated that patients treated with MegaSporeBiotic, compared with those treated with rifaximin followed by nutraceutical or low-FODMAP diet, had similar severity scores and rectal volume sensation test results for all parameters tested and statistically significant improvement in measurements of quality of life.
format Online
Article
Text
id pubmed-6770835
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67708352019-10-30 Bacillus spp. Spores—A Promising Treatment Option for Patients with Irritable Bowel Syndrome Catinean, Adrian Neag, Adriana Maria Nita, Andreea Buzea, Mihaela Buzoianu, Anca Dana Nutrients Article Dysbiosis is a condition that can cause various clinical disorders, from gastrointestinal problems to allergies or even cancer. Resetting the microbiota using antibiotics and/or probiotics could be a possible therapy for many diseases. The aim of this study was to evaluate the effects of three treatment regimens in patients with irritable bowel syndrome (IBS). The regimens were short-term rifaximin treatment (10 days) followed by either a nutraceutical agent (G1) or a low- Fermentable, Oligo-, Di-, Monosaccharide and Polyol (FODMAP) diet (24 days) (G3) or treatment with MegaSporeBiotic a mixture of spores of five Bacillus spp. for medium-term (34 days) (G2). Ninety patients with IBS without constipation were enrolled and divided into three groups (G1, G2, G3). Patients in G1 and G3 were evaluated over four visits (baseline/first day (V1), 10 days (V2), 34 days (V3), 60 days (V4)), and, those in G2 over three visits (V1, V3, V4). Severity score, quality of life, and parameters from the rectal volume sensation test were determined. The results demonstrated that patients treated with MegaSporeBiotic, compared with those treated with rifaximin followed by nutraceutical or low-FODMAP diet, had similar severity scores and rectal volume sensation test results for all parameters tested and statistically significant improvement in measurements of quality of life. MDPI 2019-08-21 /pmc/articles/PMC6770835/ /pubmed/31438618 http://dx.doi.org/10.3390/nu11091968 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Catinean, Adrian
Neag, Adriana Maria
Nita, Andreea
Buzea, Mihaela
Buzoianu, Anca Dana
Bacillus spp. Spores—A Promising Treatment Option for Patients with Irritable Bowel Syndrome
title Bacillus spp. Spores—A Promising Treatment Option for Patients with Irritable Bowel Syndrome
title_full Bacillus spp. Spores—A Promising Treatment Option for Patients with Irritable Bowel Syndrome
title_fullStr Bacillus spp. Spores—A Promising Treatment Option for Patients with Irritable Bowel Syndrome
title_full_unstemmed Bacillus spp. Spores—A Promising Treatment Option for Patients with Irritable Bowel Syndrome
title_short Bacillus spp. Spores—A Promising Treatment Option for Patients with Irritable Bowel Syndrome
title_sort bacillus spp. spores—a promising treatment option for patients with irritable bowel syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770835/
https://www.ncbi.nlm.nih.gov/pubmed/31438618
http://dx.doi.org/10.3390/nu11091968
work_keys_str_mv AT catineanadrian bacillussppsporesapromisingtreatmentoptionforpatientswithirritablebowelsyndrome
AT neagadrianamaria bacillussppsporesapromisingtreatmentoptionforpatientswithirritablebowelsyndrome
AT nitaandreea bacillussppsporesapromisingtreatmentoptionforpatientswithirritablebowelsyndrome
AT buzeamihaela bacillussppsporesapromisingtreatmentoptionforpatientswithirritablebowelsyndrome
AT buzoianuancadana bacillussppsporesapromisingtreatmentoptionforpatientswithirritablebowelsyndrome